Erdafitinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With FGFR Mutations (A Pediatric MATCH Treatment Trial)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Janssen Research & Development, LLC
Janssen Pharmaceutical K.K.
Janssen Research & Development, LLC
Janssen Research & Development, LLC
Janssen Research & Development, LLC
National Cancer Institute (NCI)
M.D. Anderson Cancer Center
Janssen Research & Development, LLC
Janssen Research & Development, LLC
National Cancer Institute (NCI)
Memorial Sloan Kettering Cancer Center
Brigham and Women's Hospital
xCures